Detalhe da pesquisa
1.
Validation of LymphGen classification on a 400-gene clinical next-generation sequencing panel in diffuse large B-cell lymphoma: real-world experience from a cancer center.
Haematologica
; 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38497151
2.
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes.
Haematologica
; 109(1): 200-208, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646672
3.
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Blood
; 137(23): 3165-3173, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33861303
4.
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.
Blood
; 137(1): 39-48, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32730585
5.
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ann Hematol
; 102(7): 1773-1787, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37171597
6.
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
Blood
; 133(20): 2121-2129, 2019 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770396
7.
Kinetics of pre-myelodysplastic syndromes blood values correlate with disease risk and survival.
Hematol Oncol
; 38(5): 782-791, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32632931
8.
Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival.
Hematol Oncol
; 36(1): 128-135, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28639416
9.
Correction to: REMIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (polaBR), CART therapies, and lenalidomide/rituximab (R2) based on realworld data in patients with relapsed/refractory diffuse large Bcell lymphoma.
Ann Hematol
; 102(9): 2643-2644, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37432417
10.
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.
Eur J Haematol
; 101(3): 399-406, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29949186
11.
Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?
Eur J Haematol
; 101(4): 502-507, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29956845
12.
Gender differences in mortality among statin users aged 80 years or more.
Z Gerontol Geriatr
; 51(8): 882-888, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29116376
13.
Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome.
Hematol Oncol
; 35(4): 734-740, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27641057
14.
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Haematologica
; 100(5): 662-9, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25661442
15.
Evaluation of a problem-specific SBAR tool to improve after-hours nurse-physician phone communication: a randomized trial.
Jt Comm J Qual Patient Saf
; 39(11): 495-501, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24294677
16.
Effect of vitamin D analogues on acute cardiorenal syndrome: a laboratory rat model.
Isr Med Assoc J
; 15(11): 693-7, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24511650
17.
Predictors of survival in patients with MALT lymphoma: a retrospective, case-control study.
Blood Adv
; 7(8): 1496-1506, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399527
18.
Very low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue.
Leuk Lymphoma
; 64(13): 2195-2201, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37706509
19.
Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.
Blood Adv
; 7(20): 6339-6350, 2023 10 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37530631
20.
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting.
Cancers (Basel)
; 15(6)2023 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36980646